Boehringer Ingelheim Vetmedica has expanded its portfolio of pig products with the launch of the first oral vaccine for the control of porcine ileitis (Porcine Proliferative Enteropathy PPE), offering producers an innovative solution to help improve economic performance in the pig.
Enterisol® Ileitis was launched to a European audience of specialist pig veterinary surgeons in Barcelona on the 14th October. Amongst the speakers at the launch symposium was Prof. Dr. Hans-Wilhelm Windhorst from the University of Vechta in Germany, who made the key note presentation highlighting the implications of the globalisation of pig production. Dr Connie Gebhardt from the University of Minnesota and Steve McOrist, one of the co-discoverers of Lawsonia Intracellularis, the infectious cause of porcine ileitis, described its discovery and pathogenisis.
The experiences of producers in Germany and Canada who have used Enterisol Ileitis have demonstrated significant improvements in live weight gain, reductions in bodyweight variability at slaughter and a reduction in days to slaughter. In Canada, the introduction of Enterisol Ileitis has resulted in a substantial decrease in the use of feed grade tylosin.
The introduction of Enterisol Ileitis in the UK and Ireland adds to Boehringer's current pig vaccine portfolio, which includes Ingelvac PRRS KV and Ingelvac M hyo. The new vaccine will ensure that the company continues to grow in significance in the domestic pig vaccine market.
